

Anticardiolipin and anti- β 2-glycoprotein 1 in Omani patients with anti-phospholipid syndrome

Adel Alnaqdy, MSc PhD* Ahmed Al-Shukaily, PhD*

Objective: Anti-cardiolipin (ACA) and anti- β 2-glycoprotein I (β 2GPI) antibodies are thought to be involved in the development of arterial or venous thrombosis, thrombocytopenia and recurrent fetal loss. We examined the presence of these autoantibodies in Omani patients with autoimmune and non-autoimmune disorders.

Methods: Sera from 30 patients with systemic lupus erythematosus (SLE; 30), 44 with a history of recurrent abortion and 36 with thrombosis/thrombocytopenia were tested for ACA and anti- β 2GPI antibodies. In addition, sera from 30 healthy subjects were also tested for these antibodies.

Results: ACA were detected in 23% with SLE, 27% suffering from recurrent abortion and 36% of patients with thrombosis/thrombocytopenia while anti- β 2GPI antibodies were detected in 16.6%, 18% and 22% of same patients, respectively.

Conclusions: Our data demonstrate a high prevalence of ACA and anti- β 2GPI antibodies of either combined or separate pattern among the Omani patient groups studied.

Bahrain Med Bull 2005;27(2):

Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin^{1,2}. High serum levels of ACA are frequently detected in patients with autoimmune (eg. SLE) and non-autoimmune diseases, as well as in apparently healthy individuals^{3,4}.

Studies have shown that plasma glycoprotein with phospholipid-binding property is required for ACA., to bind to cardiolipin that has been coated onto plastic plates. This cofactor has been identified as β 2-glycoprotein 1 (β 2GPI)^{5,6}. Later, it was found that β 2GPI is indeed the antigen to which many ACA patients are actually binding and the phospholipid merely serves to link the β 2GPI to the solid phase⁷.

Antibodies to cardiolipin and β 2GPI have been associated with an increased risk for recurrent arterial and venous thrombotic events, thrombocytopenia and fetal loss. These manifestations are the main features of the anti-phospholipid syndrome (APS)⁸⁻¹⁰. The

* Immunologists
Departments of Microbiology & Immunology
College of Medicine and Health Sciences
Sultan Qaboos University
Al-Khod 123
Sultanate of Oman

syndrome occurs in isolation (primary APS) or in association with connective tissue diseases (secondary APS), particularly SLE^{11,12}.

This study aimed to determine the prevalence of ACA and anti- β 2GPI antibodies in sera from Omani subjects with SLE, thrombosis or thrombocytopenia and in women with recurrent abortion.

METHODS

Subjects

One hundred and ten serum samples from various patient groups (83 females and 27 males; mean age was 29 ± 11 years, range: 16-64 years) were analyzed to determine ACA and anti- β 2GPI antibodies. In addition, serum from 30 healthy subjects of similar age and gender distributions were studied. Patient groups studied were diagnosed of having the following diseases (on the basis of the onset of signs, symptoms and other clinical and serologic abnormalities): SLE 30, a history of a recurrent pregnancy loss 44 and thrombosis/ thrombocytopenia 36.

RESULTS




Figure 1. Prevalence of ACA and β 2GPI in patients included in this study (n=110) and normal healthy control subjects (n=30)

Prevalence of ACA and anti- β 2GPI antibodies in both patients groups and normal subjects included in this study are shown in Figure 1 and Table 1. The percentages of positive sera for ACA and β 2GPI were 23% and 16.6% in the SLE group, 27% and 18% in the abortion group and 36% and 22% in the group with thrombosis/thrombocytopenia. In the normal healthy control group, the percentages of positive sera for ACA and anti- β 2GPI antibodies were found to be 6% and 3% respectively, with a significant difference when compared to the general picture in patients (33% and 19%).

Table 1. Prevalence of ACA and β 2GP1 in all patients groups as well as normal subject included in this study.

	SLE (n=30)	ABORTION (n = 44)	THROMBOSIS (n=36)	NORMAL (n =30)
ACA	23%	27%	36%	6%
β 2GP1	16.6%	18%	22%	3%
BOTH	10%	13.6%	19.4%	3%

The percentage of patients who possessed serum ACA but no antibody to β 2GP1 in each group was as follows: SLE (13%), abortion (13%) and thrombosis/thrombocytopenia (16%). On the other hand, percentages of subjects who tested positive for anti- β 2GP1 antibodies only (negative for ACA) in each group was as follows: SLE 5%, abortion 2% and thrombosis/thrombocytopenia 3%.

Ten percent of sera from SLE patients were positive for both ACA and anti- β 2GP1 antibodies, in the thrombosis/ thrombocytopenia group this was found to be 19.4% while in sera derived from women with history of a recurrent pregnancy loss 13% were positive for both antibodies. Among the normal healthy subjects included, 3% of the sera were also positive for both antibodies.




Figure 2. ACA and β 2GP1 levels in sera from women with history of a recurrent pregnancy loss (n=44), patients with thrombosis/thrombocytopenia (n=36), with SLE disorder (n=30) as well as with normal healthy subjects (n=30)

DISCUSSION

ACA detects a heterogeneous group of antibodies with two distinct specificities: β 2GP1-dependent and β 2GP1-independent reactivity. Sera positive in ACA assay, but negative in β 2GP1-ELISA are found in patients with infectious diseases, and exhibited lower specificity and lower positive predictive value for APS clinical features^{13,14}. In

contrast, patients whose sera were anti-β2GP1 antibodies positive and ACA negative have been reported to have a high prevalence of clinical manifestations of APS¹⁵.

Antiphospholipid antibodies are well-recognized factors in patients with SLE¹⁶. The present study confirms the high prevalence of antibodies to cardiolipin and β2GP1 in patients with SLE (23% and 16.6% of SLE respectively). Furthermore, all SLE patients who tested positive for both ACA and anti-β2GP1 antibodies had clinical manifestations of thrombosis or thrombocytopenia and, thus, were considered to be of a secondary APS type according to the classification established by Wilson et al¹⁷ which applied to patients who had persistent elevated ACA together with the systemic autoimmune disease. The risk of thrombosis associated with antiphospholipid antibodies has been studied most thoroughly in populations with systemic lupus erythematosus, of whom 12%–30% had ACA¹⁸.

The association between antiphospholipid antibodies and recurrent spontaneous abortion has also been documented^{19,20}. Autoimmune ACA may induce pregnancy failure either by impairing embryonic implantation and/or binding directly to placenta^{21,22}.

An earlier study carried on Omani patients had shown that the presence of ACA was associated with the risk of abortions²³. Our study confirmed the high presence of ACA and anti-β2GP1 antibodies in sera derived from women with a history of recurrent abortion (27% and 18%, respectively). A previous group had reported β2GP1 dependent ACA in 40% of the cases investigated²⁴. This difference may be partly explained by variations in assay protocols of various laboratories used to detect ACA or due to the immune characteristics of this population compared to those analyzed by other authors²⁵. Nevertheless, according to some reports, the frequency of ACA in recurrent pregnancy loss was found to range from 11% to 42%, which is closer to our findings^{26,27}.

ACA have been found to be strongly associated with increased risk of venous and arterial thrombosis and thrombocytopenia²⁸. The current study showed a relatively high frequency of antiphospholipid antibodies in patients with thrombosis/thrombocytopenia. A total of 36% of patients were positive for ACA, while 22% were positive for anti-β2GP1 antibodies and 19.4% of these patients were positive for both antibodies. These results were in agreement with earlier reports on a similar group of patients^{29,30}.

One of the most difficult clinical issues in APS is the lack of specificity of ACA for the diagnosis, leading to the possibility of both false positive diagnoses and unnecessary anticoagulant therapy. An increase in clinical specificity may be achieved by testing both antibodies.

CONCLUSION

Our study confirms the presence of both antibodies (in various ratios) among the patients studied. It also demonstrates a specific pattern for both ACA and anti-β2GP1 antibodies among the Omani patients studied. These are likely to contribute to the variation in results reported by different laboratories, particularly among those using the same assay.

Additional research is necessary to elucidate the relationship of the antibodies to the disease process, and to use this information towards improving diagnosis and treatment of affected patients.

REFERENCES

1. Harris EN. Annotation. Antiphospholipid antibodies. *Br J Haematol* 1990;74:1-9.
2. McNiel HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. *Adv Immunol* 1991;49:193-280.
3. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. *Ann Intern Med* 1990;112:682-8.
4. Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. *Seminars in Arthritis and Rheumatism* 1990;20:81-96.
5. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. *Lancet* 1990;335:1544 – 7.
6. Koike T, Matsuura E. What is the “true” antigen for anticardiolipin antibodies? *Lancet* 1991;337:671–2.
7. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to β 2-glycoprotein1 and clinical manifestations in patients with Systemic Lupus Erythematosus. *Arthritis and Rheumatism* 1996;39:1466–74.
8. Hughes GR. The antiphospholipid syndrome: ten years on. *Lancet* 1993;342:341-4.
9. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. *Arthritis Rheum* 1996;39:1444-54.
10. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. *Annu Rev Med* 1996;47:533-53.
11. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. *Medicine (Baltimore)* 1989;68:353-65.
12. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. *J Rheumatol* 1989;16:482-8.
13. Wagenknecht D, McIntyre J. Changes in β 2-Glycoprotein I antigenicity induced by phospholipid binding. *Thrombosis and Haemostasis* 1993;64:361-5.
14. Pengo V, Biasiolo A, Grazia Fior M. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β 2-glycoprotein I is bound to a suitable surface. *Thrombosis and Haemostasis* 1995;73:29-34.
15. Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti- β 2 glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. *J Lab Clin Med* 1997;129:499-506.
16. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-A meta-analysis. *Lupus* 1997;6:467–73.

17. Wilson WA, Gharavi A, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum.* 1999;43:1309-11.
18. Merkel PA, Chang Y, Pierangeli SS, et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. *Am J Med* 1996;101:576-83.
19. Triplett DA. Obstetrical complications associated with antiphospholipid antibodies. In: Coulam CB, Faulk WP, McIntyre JA, editors. *Immunological obstetrics*. London: Norton Medical Books 1992;377-403.
20. Kwak JYH, Barini R, Gilman-Sachs A, et al. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome. *Am J Obstet Gynecol* 1994;171:239-46.
21. Sthoeger ZM, Mozes E, Tartakovsky B. Anticardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. *Proc Natl Acad Sci USA* 1993;90:6464-7.
22. Katano K, Aoki K, Sasa H, et al. β 2-glycoprotein-I dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. *Hum Reprod* 1996;11:509-12.
23. Al Abri S, Vaclavinkova V, Richens ER. Outcome of pregnancy in patients possessing anticardiolipin antibodies. *SQU Journal for Scientific Research* 2000;2: 91–5.
24. Kumar KS, Jyothy A , Prakash MS, et al. Beta2-glycoprotein I dependent anticardiolipin antibodies and lupus anticoagulant in patients with recurrent pregnancy loss. *J Postgrad Med* 2002;48:5-10.
25. Peaceman AM, Silver RK, Mac Gregor SN, et al. Interlaboratory variation in antiphospholipid antibody testing. *Am J Obstet Gynecol* 1992;166:1780-7.
26. Unander AM, Norberg R, Hahn L, et al. Anticardiolipin antibodies and complement in ninety- nine women with habitual abortion. *Am J Obstet Gynecol* 1987;156:114-9.
27. Taylor M, Cauchi MN, Buchanan RR. The lupus anticoagulant, anticardiolipin antibodies, and recurrent miscarriage. *Am J Reprod Immunol* 1990;23:33-6.
28. Olee T, Pierangeli S, Handley H. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. *Proc Natl Acad Sci* 1996;93:8606-11.
29. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood* 1995;86:3685–91.
30. Wahl DG, De Maistre E, Guillemin F, et al. Antibodies against phospholipids and β 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. *Q J Med* 1998;91:125–30.